Compile Data Set for Download or QSAR
Report error Found 12 Enz. Inhib. hit(s) with all data for entry = 10657
TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557699(US11466027, Compound 1l | US11358971, Compound 1h)
Affinity DataKi:  63nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557694(US11466027, Compound 1e | US11358971, Compound 1c)
Affinity DataKi:  96nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557693(US11466027, Compound 1d | US11358971, Compound 1b)
Affinity DataKi:  140nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557667(US11466027, Compound 1c | US11358971, Compound 1a)
Affinity DataKi:  170nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557701(US11466027, Compound 1n | US11358971, Compound 1j)
Affinity DataKi:  180nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557698(US11466027, Compound 1k | US11358971, Compound 1g)
Affinity DataKi:  220nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557702(US11466027, Compound 1o | US11358971, Compound 1k)
Affinity DataKi:  260nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557697(US11466027, Compound 1i | US11358971, Compound 1f)
Affinity DataKi:  360nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557703(US11466027, Compound 1p | US11358971, Compound 1l)
Affinity DataKi:  490nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557696(US11466027, Compound 1h | US11358971, Compound 1e)
Affinity DataKi:  690nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557695(US11466027, Compound 1g | US11358971, Compound 1d)
Affinity DataKi:  860nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 1(Human)
H. Lundbeck

US Patent
LigandPNGBDBM557700(US11466027, Compound 1m | US11358971, Compound 1i)
Affinity DataKi:  3.90E+3nMAssay Description:To determine the affinity of the compounds of the present invention a SPA is used. The assay is run in a 384-plate format (OptiPlate-384) where each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent